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where the small available subject pool limits our ability to perform meaningfully powered trials
with traditional cognitive and functional outcome measures.
Methods: We investigated a composite atrophy index in 26 PPA participants with longitudinal MRIs
separated by 2 years. Rogalski et al. [5] previously demonstrated that atrophy of the left perisylvian
temporal cortex (PSTC) is a highly sensitive measure of disease progression in this population and a
promising endpoint for clinical trials. Using methods described by Ard et al. [1], we constructed a
composite atrophy index composed of a weighted sum of volumetric measures of 10 regions of inter-
est within the left perisylvian cortex using weights that maximize signal-to-noise and minimize sam-
ple size required of trials using the resulting score. Sample size required to detect a fixed percentage
slowing in atrophy in a 2-year clinical trial with equal allocation of subjects across arms and 90%
power was calculated for the PSTC and optimal composite surrogate biomarker endpoints.
Results: The optimal composite endpoint required 38% fewer subjects to detect the same percent
slowing in atrophy than required by the left PSTC endpoint.
Conclusions: Optimal composites can increase the power of clinical trials and increase the probabil-
ity that smaller trials are informative, an observation especially relevant for PPA but also for related
neurodegenerative disorders including Alzheimer’s disease.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Clinical trials of interventions to slow the course of
chronic progressive neurodegenerative diseases typicallyuthor. Tel: 11-848-246-1250; Fax: 11-858-246-
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commons.org/licenses/by-nc-nd/4.0/).use cognitive neuropsychometric and functional (activities
of daily living) outcome measures to demonstrate efficacy.
Treatment efficacy is difficult to demonstrate with these end-
points, because decline is subtle during the relatively short
span of observation of a clinical trial, and because there is
substantial random variability in these measures from person
to person and from observation to observation within a per-
son. Volumetric magnetic resonance imaging (MRI) on the
other hand has been shown to have good signal-to-noiseimer’s Association. This is an open access article under the CC BY-NC-ND
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tia of the Alzheimer type (AD), a substantial literature has
consistently demonstrated that volumetric MRI endpoints
could reduce required sample size in AD treatment trials
and secondary prevention trials of mild cognitive impair-
ment by 75% ormore compared to a standard cognitive func-
tion outcome [1]. The need for efficient endpoints is
especially critical for rare subtypes of disease where the
pool of subjects available for recruitment limits our ability
to even perform large-scale phase 3 trials using neuropsy-
chometric and functional outcome measures.
Primary progressive aphasia (PPA) is a clinical dementia
syndrome characterized by an initially isolated and progres-
sive decline in language function and is associated with peak
atrophy within the left hemisphere perisylvian language
network [2–4]. Rogalski et al. [5] demonstrated that atrophy
of the left perisylvian temporal cortex in particular is a high-
ly sensitive measure of disease progression and a promising
endpoint for clinical trials. Using this endpoint, clinical trials
as small as 10 participants per arm would have 80% power to
detect a 40% slowing of atrophy [5]. Efficiency of trials may
be improved beyond these impressive levels by efficient uti-
lization of the richness of data obtained byMRI. Xiong et al.
[6] proposed that “composite” endpoints calculated as
weighted averages of volumetric region of interest (ROI)
substructures may outperform simple sums. These methods
were operationalized by Ard et al. [7], who derived algo-
rithms for determining optimal composite measures that
maximize statistical power when used as an endpoint for
clinical trials. In this brief communication, we demonstrate
the potential utility of composite atrophy measures for clin-
ical trials of neurodegenerative diseases with a prominent at-
rophy component.Fig. 1. Regions of interest used to examine longitudinal cortical atrophy in
PPA. Top: The perisylvian temporal cortex region of interest defined in Ro-
galski et al. [5]. Bottom: the regions of interest used to create the composite
outcome measure.2. Methods
Study subjects and imaging techniques have been previ-
ously described [5]. Briefly, study subjects included 26 indi-
viduals with a root diagnosis of PPA [2–4] (8 PPA logopenic,
10 PPA agrammatic, 8 PPA semantic). For the purposes of
this article, the three clinical subtypes of PPA were
combined to insure sufficient sample size to estimate
parameters required for calculating weights. Hence, this
analysis is best interpreted as a proof-of-concept demonstra-
tion of the potential utility of composite volumetric mea-
sures, rather than derivation of an endpoint appropriate for
use in a clinical trial. Mean age at baseline was 63.7 years
(SD 5 6.7), 58% were women, mean Boston Naming Test
scorewas 39.5 (SD5 20.9), and meanWestern Aphasia Bat-
tery Aphasia Quotient score was 86.8 (SD 5 8.0). All sub-
jects received a baseline structural MRI and follow-up
MRI approximately 2 years later (mean interval 2.0 years).
Structural MRIs were processed using the cross-sectional
[8] and longitudinal [9] pipelines from FreeSurfer, version
5.1.0. Ten regions of interest (ROIs) within the left perisyl-
vian temporal cortex region (Fig. 1) taken from the auto-mated Desikan–Killiany cortical parcellation atlas were
the components of a composite outcome measure [10].
The composite was calculated as the optimally weighted
sum of these ROIs using weights that maximize the signal-
to-noise ratio of rate of change on the composite, as previ-
ously described [7]. Clinical trail endpoints with high
signal-to-noise ratio, also called the mean to standard devi-
ation ratio (MSDR), are more sensitive to treatment effects
and optimize the power of a trial. We used relative efficiency
to compare the performance of different outcome measure,
where relative efficiency is defined as the ratio of sample
size required for trials using the respective outcomes calcu-
lated using the standard formula for a two-sample t test:
n=arm52

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2
s2d
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where s2d is the within group variance of the outcome mea-
sure being compared across treatments, in this case, the
change from baseline to 2-year follow-up, D is the treatment
effect size under the alternative, and z12a/2 and z12b are the
usual quantiles of the standard normal distribution, with a
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Indexing two trial outcomemeasures to be compared as A
and B, the relative efficiency of outcome A to outcome B is
defined as
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Let mA and mB represent the mean change under placebo
for outcome measures A and B, respectively. We can express
effect sizes as proportional slowing of mean rate of change.
For example, to power for a treatment effect that slows atro-
phy by 25%, we would set DA 5 0.25! mA and DB 5 0.25
! mB. Expressing effect sizes in this way, the proportions
and the terms involving a and b drop out of the relative ef-
ficiency formula, leading to a simple function of MSDRs
of the two instruments being compared:
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
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2
B
!100%5
MSDR2B
MSDR2A
!100%
For example, a relative efficiency of 50%means a trial us-
ing instrument A would require half as many subjects as a
trial using instrument B to detect the same percent slowing
in rate of decline.3. Results
Mean rate of decline and person-to-person variability in
rate of decline are summarized in the Table 1. The MSDR
for the referent total left perisylvian temporal cortical volume
endpoint is 3.90. TheMSDR for the component subregions ofTable 1
Test characteristics and relative efficiency of various potential clinical trial outcom
Measure
FreeSurfer
region of interest
Mean
year d
Boston Naming Test (maximum score: 60) 15
Western aphasia battery -revised, aphasia
quotient (maximum score: 100)
22
Total cortical volume (mm3) rh.cortex 1 lh.cortex 29,397
Left perisylvian temporal cortex (mm3) 7811
Components, optimal composite
Left superior temporal gyrus (mm3) lh.superiortemporal 1041
Left middle temporal gyrus (mm3) lh.middletemporal 1128
Left inferior temporal gyrus (mm3) lh.inferiortemporal 955
Left banks, sup. temp. sulcus (mm3) lh.bankssts 214
Left fusiform gyrus (mm3) lh.fusiform 810
Left transverse temporal gyrus (mm3) lh.transversetemporal 80
Left temporal pole (mm3) lh.temporalpole 180
Left inferior frontal gyrus (mm3) ymultiple regions 768
Left inferior parietal gyrus (mm3) lh.inferiorparietal 1075
Left Supramarginal gyrus (mm3) lh.supramarginal 880
Optimal composite index 252
*Two-year clinical trial comparing change baseline to year 2 in treatment versu
ylh.parsopercularis 1 lh.parstriangularis 1 lh.parsorbitalis.the left perisylvian temporal cortex range from 1.58 to 3.36,
consistently below the MSDR of the left perisylvian temporal
cortex, meaning that components individually would be less
sensitive to atrophy than the full perisylvian ROI. The
MSDR of the composite atrophy measure is 4.95, over 25%
larger than the left perisylvian temporal cortex MSDR. In
terms of relative efficiency, the optimal composite endpoint
requires 38% fewer subjects than the total perisylvian tempo-
ral cortex volume measure to detect the same percent slowing
in atrophy. For example, with 90% power, only 15 subjects
per arm would be required to detect a 25% slowing in rate
of progression in the composite outcome measure assuming
the distribution of decline observed in our pilot study.
For comparison, we also report relative efficiency and sam-
ple size projections for clinical trials using total cortical volume
or specific neuropsychometric instruments as the primary
outcomemeasure. Relative to the full perisylvian temporal cor-
tex ROI, the total cortical volume endpoint would require 40%
more subjects, and the neuropsychometric outcomes would
require more than ten times more subjects per arm (Table 1).4. Discussion
We have described a relatively intuitive and accessible
volumetric composite index defined simply as the (opti-
mally) weighted sum of ROI volumes. In our example, the
resulting outcome measure substantially improved the effi-
ciency of clinical trials in PPA, reducing required sample
size relative to the total perisylvian cortical volume outcome
by 38%. Other summaries of MRI data for this purpose have
been proposed. Less intuitive and accessible perhaps are
mathematically derived atrophy indexes, for example, the
weighted average of vertices summarizing ventricular
morphometry [11]. In the other extreme, using the singlees measures
2
ecline
Standard deviation
of 2-year decline MSDR
Relative
efficiency
N/arm to detect
25% slowing*
.7 14.2 1.10 11.08 277/arm
.9 18.2 1.26 8.60 215/arm
10,526 2.79 1.40 35/arm
2004 3.90 1.00 25/arm
310 3.36
403 2.79
297 3.22
71 3.00
287 2.82
50 1.58
102 1.77
345 2.23
417 2.58
352 2.50
51 4.93 0.62 15/arm
s control, two-sided test, a 5 0.05, power 5 90%.
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temporal cortex in PPA [5] or the hippocampus [1] or frontal
lobe [11] in AD is perfectly intuitive and accessible. Deter-
mining the relative efficiency of these various approaches, as
we have demonstrated here, will be a useful tool for clini-
cians weighting the tradeoffs of accessibility versus power
when selecting endpoints for clinical trials.
There are limitations to this report. The relatively small
sample size in this cohort and lack of information about
the underlying neuropathology required pooling of etiologi-
cally disparate disease entities for the purpose of demon-
strating the optimal compositing methodology. Hence,
sample size estimates from this report are only for illustra-
tive purposes. We emphasize that meaningful estimation of
optimal weighting parameters will require substantially
larger, representative samples than used in this proof-of-
concept demonstration. To simplify presentation, we
ignored the influence of “normal” age-associated atrophy.
Age-associated atrophy may not respond to treatment, and
ignoring the influence of age-associated atrophy may lead
to under estimation of detectible effect size and overstate-
ment of power. This is a substantial concern for typical am-
nestic AD [12,13]; but is less of an issue for PPA, where
onset age is typically ,65 years, and there is a rapid rate
of disease-associated atrophy relative to normal aging.
Thus age-associated atrophy is likely to have a negligible ef-
fect on the relative efficiency calculations that are the focus
of this manuscript. Finally, an implicit assumption of the
optimal compositing method is that treatment slows the
rate of atrophy proportionally in all ROIs. This is a plausible
assumption, but one that cannot be formally tested until an
effective treatment is identified.
Biomarker endpoints have clear limitations. There is no
guarantee that treatments positively affecting biomarkers will
have corresponding effects on cognitive and functional out-
comes, and biomarkers will have been validated as surrogates
for clinical endpoints before they will be approved as primary
endpoints for phase 3 clinical trials [14]. However, surrogate
endpoints including volumetric MRI are currently being used
in phase 2 trials, to demonstrate target engagement, and to
guide the choice of compounds to move forward to phase 3
[15]. To this end, volumetric endpoints are certainly suggested
for diseases like PPAwith a prominent atrophy component.
Clinical trials of chronic progressive disease are prohibi-
tively expensive. In AD research, this has limited our ability
to test new treatments and find a cure for the disease. For less
common phenotypes such as the subtypes of PPA, the need
for more efficient endpoints is even more pressing because
the available participant pool for clinical trials is limited.
Every participant enrolled in a clinical trial is a precious
resource, and methods to optimally use all information ob-
tained from participants enrolled in clinical trials and
increase the probability that effective treatments are identi-
fied should be fully investigated. Optimal weighting maxi-
mizes signal-to-noise of endpoints and statistical efficiency
of trials. To our knowledge, this is the first meaningful appli-cation of optimal weighting to volumetric MRI measures.
The real world context is need for more cost-effective and
informative clinical trials to speed the development of treat-
ments for neurodegenerative diseases. Primary progressive
aphasia, a relatively rare (limited subject pool) disease with
prominent atrophy component, is perhaps the perfect labora-
tory for investigating the performance of alternative surro-
gate volumetric MRI biomarker endpoints for clinical trials.
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1. Systematic review: Rogalski et al. [5] previously
demonstrated that atrophy of the left perisylvian
temporal cortex is a highly sensitive measure of
disease progression in primary progressive aphasia
and a promising endpoint for clinical trials. Using
methods described by Ard et al. [1], we constructed a
composite atrophy index composed of an optimally
weighted linear combination of focal volumetric
measures from 10 ROIs within the left perisylvian
temporal cortex. Optimal weighting maximizes
signal-to-noise and statistical efficiency of clinical
trials, and in this application e.g., reduced sample
size requirements by 38%.
2. Interpretation: Optimal composite outcome mea-
sures show promise as a way improved efficiency
of trials. More cost-effective and informative clinical
trials would speed the development of treatments for
neurodegenerative diseases.
3. Future directions: This proof of concept analysis
demonstrated the potential utility of composite volu-
metric measures to improve the efficiency of trials.
We will need larger datasets representative of future
clinical trials to more definitively establish the utility
of these methods.
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